Recombinant Anti-DcR2/TRAIL R4 Antibody, Rabbit Monoclonal

EliteRmab®, manufactured by recombinant technology
1/2
Price:
Size:
Number:

Recombinant Anti-DcR2/TRAIL R4 Antibody, Rabbit Monoclonal General Information

Product name
Recombinant Anti-DcR2/TRAIL R4 Antibody, Rabbit Monoclonal
Validated applications
IHC-P
Species reactivity
Reacts with: Human
Specificity
Human DcR2/TRAIL R4
No cross-reactivity in ELISA with
Human TNFRSF10A
Human TNFRSF10B
Human TNFSF10
Human TNFα
Human TNFβ
Immunogen
Recombinant Human TRAIL R4 / CD264 / TNFRSF10D protein (Catalog#10413-H08H)
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human TRAIL R4 / CD264 / TNFRSF10D (rh TRAIL R4 / CD264 / TNFRSF10D; Catalog#10413-H08H; NP_003831.2; Met1-His211).
Source
Monoclonal Rabbit IgG Clone #009
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Recombinant Anti-DcR2/TRAIL R4 Antibody, Rabbit Monoclonal Validated Applications

Application Dilution
IHC-P 1:100-1:500
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Recombinant Anti-DcR2/TRAIL R4 Antibody, Rabbit Monoclonal Images

Immunochemical staining of human TNFRSF10D in human placenta with rabbit monoclonal antibody (1:200, formalin-fixed paraffin embedded sections). Positive staining was localized to trophocyte.
Immunochemical staining of human TNFRSF10D in human kidney with rabbit monoclonal antibody (1:200, formalin-fixed paraffin embedded sections). Positive staining was localized to kidney tubules and colleting duct.

Recombinant Anti-DcR2/TRAIL R4 Antibody, Rabbit Monoclonal: Synonyms

Anti-CD264 Antibody; Anti-DCR2 Antibody; Anti-TRAIL-R4 Antibody; Anti-TRAILR4 Antibody; Anti-TRUNDD Antibody

DcR2/TRAIL R4 Background Information

Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D), also known as TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4), CD264, and Decoy receptor 2, is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. TRAIL R4/CD264/TNFRSF10D is widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. TRAIL R4/CD264/TNFRSF10D is also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. The signaling capacity of TRAIL R4 is similar to that of TRAIL R1 and TRAIL R2 with respect to NF-κB activation, but differs in its inability to induce apoptosis. TRAIL R4 retains a C-terminal element containing one third of a consensus death domain motif. Transient overexpression of TRAIL R4 in cells normally sensitive to TRAIL-mediated killing confers complete protection, suggesting that one function of TRAIL R4 may be inhibition of TRAIL cytotoxicity.
Full Name
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain
Related Pathways
  • Death Receptor Signaling
    Death Receptor Signaling
References
  • Degli-Esposti MA, et al. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7(6): 813-20.
  • Meng RD, et al. (2000) The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther. 1(2): 130-44.
  • Bouralexis S, et al. (2003) Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer. 89(1): 206-14.

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.